CBIS Sets the Stage for High-Growth Amidst DEA Historical National Industry Changes for Critical Ailment Treatments & Historic California Voting in November
LOS ANGELES, June 30, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced the relocation of their corporate headquarters to Irvine, California. The company’s HQ move to California will put them in closer proximity to its vital laboratory resources, key distributors, and many patients. This move will help the company cut costs, decrease time to market for new products, and perform clinical trials more efficiently with a new California laboratory, clinical trials unit, and medical treatment facility to be announced shortly.
CBIS looks to target the high growth projected in the national industry changes, such as the possible DEA reclassification of cannabis which can positively multiply the efforts of the Company’s scientific team dramatically, and the Historic California voting in November.
These changes can open the markets dramatically for the Company’s proprietary cannabinoid formulations being created to be distributed nationwide. The urgent objective is the treatment of critical ailments, such as, various Cancers, HIV/AIDS, Pain Management, Autism, PTSD, and other neurological conditions. Though this list represents only a handful of the targeted ailments we hope to treat, it reflects some of the serious medical afflictions we are dealing with. The Company fully understands that while the price is high, one blockbuster pharmaceutical drug can change the framework forever in Cannabis Science, and the Company believes it has more than one.
While the Company negotiates to close a new deal with its North California property partners it continues forward with creating lab expansions for IGXBio’s GenePro FDA Investigational New Drug (IND) Number 015982 for further drug development to identify & develop agonist cannabinoids for GenePro, closing large educational & cultivation property development deals utilizing the strengths of Universities.
We feel empowered and strengthened with clinical drug development confidence as GW Pharma announces positive results with its CBD-Based Epilepsy formulation while mapping out its own critical ailment drug development plans for many critical ailments based on successful self-medicating cannabinoid cancer treatments and other amplified results. Cannabis Science Europe GmbH, a European subsidiary of Cannabis Science Inc., based in Germany released the newest innovative product lines through its partners http://www.dupetit.eu/ .
In a highly successful delegation trip to South Africa and Namibia, CBIS launches a historic African healthcare-initiative led by Co-Founder and CEO Mr. Raymond C. Dabney, all while he extends his hands with loyalty gifts to shareholders; the sentiment is simple.
“Shall we demand our rightful place or shall we be patient and endure all growth changes as they come so we can reap the rewards of a job well done? The Company believes the answer is obvious,” said President, CEO, and Co-Founder, Mr. Raymond C. Dabney, Cannabis Science Inc. “With such a large shareholder base asking so many questions from so many cities and countries from all around the world, CBIS is implementing a new set of briefing procedures for “on the go” progress reports and free flowing support valves for each of its many important projects and expects it to be very well received when it is launched.
“We are excited to be able to build a much stronger company at the right time, right in the midst of all these Historic industry changes. It seems we are always setting our bar higher, our relationships become stronger, our supply and distribution chains gain momentum now that there are more progressive cannabis laws being applied. Cannabis Science has a heritage of change and a corporate culture that seeks out the doctrine, strategies, tactics and procedures to enable its scientific capabilities to flourish and provide sound critical ailment solutions within the cannabinoid-based pharmaceutical industry.
“There are many technological advancements in the science of cannabinoids in various regions around the world, many of which are making History. We are very proud to be one of them. These ground-breaking advancements are more exciting than ever. It is profound that we have this opportunity to be right in the middle of such powerful changes in the pharmaceutical industry enabling more Companies to address the world’s most horrific medical afflictions.
“We are targeting so many critical ailments while we are at such an important intersection, with the DEA reclassification at hand, we must and we will, continue to identify and implement ways in which Cannabis Science can bring an asymmetric advantage to all this. Be assured that we are all blessed and this is extremely outstanding and compelling for all those with us,” said President, CEO, and Co-Founder, Mr. Raymond C. Dabney, Cannabis Science Inc.
The company’s new Corporate Headquarters address will be 19800 MacArthur Blvd., Suite 300, Irvine, California 92612, and the contact number will remain the same. The California HQ is temporary as the Company is looking at Washington, DC as its next and possible final fully functional HQ. The company’s hours of contact will be between 9:00 am and 5:00 pm Pacific Standard Time.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3028788